Taken together, our multi-pronged approach using ectopic co-expression to demonstrate cooperation of Aurora A and JAK2 to transform normal cells as well as the genetic silencing and the pharmacological inhibition of these kinases in human cancer cells, support the notion that the combination treatment targeting both Aurora A and JAK2 pathways might be more beneficial to some cancer patients. The gene discussed is JAK2; the disease is cancer.